Clinical Trial Update: TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 open-label trial evaluating rociletinib versus single-agent cytotoxic chemotherapy in EGFR-mutant NSCLC after prior EGFR-TKI and platinum therapy; trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• rociletinib (rociletinib)

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2019-07-23